DM
TVRD

Deerfield Management’s Tvardi Therapeutics TVRD Stock Holding History

Deerfield Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-13,155
Closed -$4.76M – 137
2015
Q1 		$4.76M Hold
13,155
– – 0.15% 85
2014
Q4 		$4.72M Buy
13,155
+2,516
+24% +$810K 0.17% 82
2014
Q3 		$3.21M Buy
+10,639
New +$4.37M 0.12% 106

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Deerfield Management's TVRD Position: Q2 2015 in Review

Deerfield Management sold out of Tvardi Therapeutics (TVRD) in Q2 2015, closing a stake of 13,155 shares — an estimated $4.76M sold.

Deerfield Management first reported a position in TVRD in Q3 2014 and held it in 3 quarters. The position peaked at $4.76M in Q1 2015. 75 funds tracked by Wall St. Rank hold TVRD as of Q2 2015.

  • Deerfield Management reported no remaining Tvardi Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Deerfield Management sold 13,155 Tvardi Therapeutics shares in Q2 2015, an estimated $4.76M.
  • Deerfield Management first reported a position in Tvardi Therapeutics in Q3 2014 and held it in 3 quarters.
  • Deerfield Management's Tvardi Therapeutics position peaked at $4.76M in Q1 2015.
  • 75 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2015.

Based on Deerfield Management's 13F filing for Q2 2015, filed 14 Aug 2015.